Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2015-07-14 | survivin-based peptide antigens formulated in the DepoVax™ adjuvanting platform | Immunovaccine Technologies (Canada) | ovarian cancer |
Granting of a patent |
2015-06-23 | (1OR)-7-amino-12-fluoro-2,10,16-trimethyl-15 oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile | Pfizer (USA - NY) | anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer |
Granting of the orphan status in the US |
2015-07-07 | ANA-conjugated dactunomycin nanoemulsion | NanoSmart Pharmaceuticals (USA - CA) | Ewing sarcoma |
Granting of the orphan status in the US |
2015-07-23 | adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex | Ziopharm Oncology (USA - MA) | malignant glioma |
Granting of the orphan status in the US |
2015-07-30 | 1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide | Cleave Biosciences (USA - CA) | multiple myeloma |
Granting of a patent |
2015-07-20 | amantadine hydrochloride | Osmotica Pharmaceutical (USA - NC) | levodopa-induced dyskinesia |
Granting of the orphan status in the US |
2015-06-16 | 2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid | Rgenix (USA - NY) | glioblastoma multiforme |
Granting of the orphan status in the US |
2015-06-16 | 2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid | Rgenix (USA - NY) | ovarian cancer |
Granting of the orphan status in the US |
2015-06-23 | 2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid | Rgenix (USA - NY) | malignant melanoma stages IIB to IV |
Granting of the orphan status in the US |
2015-07-14 | 3-(4-(1,5-Napthrydine)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine) | La Jolla Pharmaceutical (USA - CA) | fibrodysplasia ossificans progressiva |
Granting of the orphan status in the US |
2015-07-16 | ombitasvir/paritaprevir/ritonavir and dasabuvir | Abbvie (USA - IL) |
|
Granting of the orphan status in the US |
2015-07-14 | thioureidobutyronitrile | Cellceutix (USA - MA) | ovarian cancer | Granting of the orphan status in the US |
2015-07-16 | recombinant humanized anti-matrix metalloprotein 9 (MMP9) monoclonal antibody IgG4 | Gilead Sciences (USA - CA) | gastric cancer |
Granting of the orphan status in the US |
2015-07-14 | recombinant multimerized human IgG1 Fc | Pfizer (USA - NY) | chronic inflammatory demyelinating polyneuropathy (CIDP) |
Granting of the orphan status in the US |
2015-07-14 | vitamin A palmitate | Advent Therapeutics (USA - PA) | prevention of bronchopulmonary dysplasia |
Granting of the orphan status in the US |
2015-07-23 | procaspase-activating compound 1 | Vanquish Oncology (USA - IL) | malignant glioma |
Granting of the orphan status in the US |
2015-07-08 | propranolol and etodolac | Vicus Therapeutics (USA - NJ) | malignant glioma | Granting of the orphan status in the US |
2015-06-16 | recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter | Nationwide Children\'s Hospital (USA - OH) | Duchenne muscular dystrophy |
Granting of the orphan status in the US |
2015-06-04 | round gel-filled smooth breast implants | Allergan (Ireland) | breast reconstruction |
Granting of a Market Authorisation in the US |
2015-02-27 | levonorgestrel-releasing intrauterine system | Actavis (Ireland) | contraception |
Granting of a Market Authorisation in the US |
© 2024 Biopharmanalyses - Powered by Samacom+